Bactiguard Valuation Multiples

Bactiguard is valued at $57M as of October 2026, a 3.1x revenue multiple. In the last 12 months, Bactiguard revenue was $22M and Bactiguard EBITDA was $3M.

Bactiguard Overview

About Bactiguard

Bactiguard Holding AB is a medical device company. It is engaged in the development of infection prevention solutions, which reduce the risk of infections and the use of antibiotics. Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. Its portfolio contains urinary catheters, endotracheal tubes, central venous catheters, Hydrocyn for disinfection and wound care, as well as sutures and other wound care products. Its geographical segments are United States, Sweden, Malaysia, China, Thailand, Bangladesh, New Zeeland, and Other countries.


Founded

2005

HQ

Sweden

Employees

177

Financials (LTM)

Revenue: $22M
EBITDA: $3M

EV

$68M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bactiguard Financials

Bactiguard reported last 12-month revenue of $22M and EBITDA of $3M.

In the same LTM period, Bactiguard generated $19M in gross profit, $3M in EBITDA, and had net loss of ($2M).

Revenue (LTM)


Bactiguard P&L

In the most recent fiscal year, Bactiguard reported revenue of $22M and EBITDA of $4M.

Bactiguard is unprofitable as of last fiscal year, with gross margin of 86%, EBITDA margin of 19%, and net margin of (4%).

See analyst estimates for Bactiguard
LTMLast FY202320242025202620272028
Revenue$22M$22M$21M$26M$22M
Gross Profit$19M$19M$15M$22M$19M
Gross Margin86%86%69%85%86%
EBITDA$3M$4M($8M)$3M$4M
EBITDA Margin15%19%(38%)10%19%
EBIT Margin(7%)(3%)(67%)(16%)(3%)
Net Profit($2M)($790K)($15M)($3M)($790K)
Net Margin(9%)(4%)(68%)(12%)(4%)
Net Debt-$9M---

Financial data powered by Morningstar, Inc.

Bactiguard Stock Performance

Bactiguard has current market cap of $57M, and enterprise value of $68M.

Market Cap Evolution


Bactiguard's stock price is $1.62.

Bactiguard share price increased by 2.8% in the last 30 days, and decreased by 12.8% in the last year.

Bactiguard has an EPS (earnings per share) of $-0.02.

See more trading valuation data for Bactiguard
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$68M$57M0.1%2.8%-7.6%-12.8%$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bactiguard Valuation Multiples

Bactiguard trades at 3.1x EV/Revenue multiple, and 20.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Bactiguard

EV / Revenue (LTM)


Bactiguard Financial Valuation Multiples

As of October 18, 2026, Bactiguard has market cap of $57M and EV of $68M.

Bactiguard has a P/E ratio of (27.9x).

LTMLast FY202320242025202620272028
EV/Revenue3.1x3.1x3.2x2.7x3.1x
EV/EBITDA20.4x16.7x(8.4x)26.0x16.7x
EV/EBIT(44.2x)(90.0x)(4.7x)(17.0x)(90.0x)
EV/Gross Profit3.6x3.7x4.6x3.1x3.7x
P/E(27.9x)(71.9x)(3.9x)(18.1x)(71.9x)
EV/FCF212.5x(94.0x)(10.7x)63.6x(94.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bactiguard Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bactiguard Margins & Growth Rates

Bactiguard decreased revenue by 1% and EBITDA by 27% in the last fiscal year.

In the most recent fiscal year, Bactiguard reported gross margin of 86%, EBITDA margin of 19%, and net margin of (4%).

See estimated margins and future growth rates for Bactiguard

Bactiguard Margins

Last FY202420252026202720282029
Gross Margin86%85%86%86%
EBITDA Margin19%10%19%14%
EBIT Margin(3%)(16%)(3%)(9%)
Net Margin(4%)(12%)(4%)(11%)
FCF Margin(3%)4%(3%)4%

Bactiguard Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)19%(15%)(1%)
Gross Profit Growth0%48%(15%)0%
EBITDA Growth(27%)(132%)56%(27%)
EBIT Growth144%(72%)(81%)144%
Net Profit Growth195%(78%)(75%)195%
FCF Growth(225%)(117%)(168%)(225%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Bactiguard Operational KPIs

Bactiguard's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Bactiguard's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bactiguard's Rule of X is 12% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Bactiguard
LTMLast FY202320242025202620272028
Rule of 4023%13%---
Bessemer Rule of X36%12%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.1M---
Opex to Revenue-89%136%101%89%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bactiguard Competitors

Bactiguard competitors include Pangaea Oncology, Daxor, K Pharma, Lumos Diagnostics Hldgs, Envoy Medical, RenovoRx, BATM Advanced Communications, Saluda Medical, Osang Healthcare and FluoGuide.

Most Bactiguard public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Pangaea Oncology$16M($1M)3.8x3.6x(58.0x)(19.3x)
Daxor$10M-5.7x6.7x--
K Pharma-($6M)--(7.9x)-
Lumos Diagnostics Hldgs$13M($412K)3.8x3.2x(122.5x)(8.9x)
Envoy Medical$241K($22M)136.2x139.8x(1.5x)-
RenovoRx$1M($12M)37.7x12.8x(3.7x)-
BATM Advanced Communications$123M$18M0.3x0.4x2.1x-
Saluda Medical$90M($142M)0.5x0.4x(0.3x)(0.4x)

This data is available for Pro users. Sign up to see all Bactiguard competitors and their valuation data.

Start Free Trial

Acquisitions by Bactiguard

Bactiguard has acquired 1 company to date.

Last acquisition by Bactiguard was on March 2nd 2020. Bactiguard acquired Vigilenz for $7M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Bactiguard

Vigilenz
Description
Vigilenz is an Australia-headquartered manufacturer of wound care and infection prevention medical devices. Product lines include absorbable and non-absorbable sutures, synthetic hernia meshes, HYDROCYN aqua as a debridement and cleaning solution for chronic wounds, plus Bactiguard-coated orthopedic trauma implants to combat surgical site infections. The company supplies hospitals, clinics, and distributors throughout Australia, New Zealand, and Southeast Asia, emphasizing antimicrobial technologies licensed from global partners.
HQ CountryMalaysia
HQ City
Penang
Deal Date2 Mar 2020
Valuation$7M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bactiguard acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bactiguard

When was Bactiguard founded?Bactiguard was founded in 2005.
Where is Bactiguard headquartered?Bactiguard is headquartered in Sweden.
How many employees does Bactiguard have?As of today, Bactiguard has over 177 employees.
Who is the CEO of Bactiguard?Bactiguard's CEO is Christine Lind.
Is Bactiguard publicly listed?Yes, Bactiguard is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Bactiguard?Bactiguard trades under BACTI B ticker.
When did Bactiguard go public?Bactiguard went public in 2014.
Who are competitors of Bactiguard?Bactiguard main competitors include Pangaea Oncology, Daxor, K Pharma, Lumos Diagnostics Hldgs, Envoy Medical, RenovoRx, BATM Advanced Communications, Saluda Medical, Osang Healthcare, FluoGuide.
What is the current market cap of Bactiguard?Bactiguard's current market cap is $57M.
What is the current revenue of Bactiguard?Bactiguard's last 12 months revenue is $22M.
What is the current revenue growth of Bactiguard?Bactiguard revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Bactiguard?Current revenue multiple of Bactiguard is 3.1x.
What is the current EBITDA of Bactiguard?Bactiguard's last 12 months EBITDA is $3M.
What is Bactiguard's EBITDA margin?Bactiguard's last 12 months EBITDA margin is 15%.
What is the current EV/EBITDA multiple of Bactiguard?Current EBITDA multiple of Bactiguard is 20.4x.
What is the current FCF of Bactiguard?Bactiguard's last 12 months FCF is $321K.
What is Bactiguard's FCF margin?Bactiguard's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of Bactiguard?Current FCF multiple of Bactiguard is 212.5x.
How many companies Bactiguard has acquired to date?As of October 2026, Bactiguard has acquired 1 company.
What was the largest acquisition by Bactiguard?$7M acquisition of Vigilenz on 2nd March 2020 was the largest M&A Bactiguard has done to date.
What companies Bactiguard acquired?Bactiguard acquired Vigilenz.
In how many companies Bactiguard has invested to date?Bactiguard hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Bactiguard

Lists including Bactiguard

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial